Sign in
AVXT Stock Price, Chart, Stats & News
AVAX Technologies, Inc.
Save
AVAX Technologies, Inc. (AVXT) does not currently pay a dividend.
6,894
Market cap
–
Current P/E
–
Forward P/E
AVXT chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on pioneering autologous cell vaccine methods for cancer therapy. Its pipeline includes lead candidates M-VAX, for melanoma, and O-VAX, targeting ovarian cancer, both of which have successfully concluded Phase II clinical trials. The firm is also developing LungVax, a potential treatment for non-small cell lung cancer.
Similar securities
Based on sector and market capitalization
Report issue